StockData
Pliant Therapeutics, Inc. logo

Pliant Therapeutics, Inc. (PLRX) stock

PLRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 3/30
$0.66−0.03 (-4.76%)

Close on Nov 17, 2026Market cap $40.88MP/E –Yield 0.00%

Pliant Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Pliant Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$70.90M. For fiscal 2025 it was -$128.34M. The highest annual figure on record is -$2.75M in fiscal 2019.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$128.34M–
FY2024Dec 31, 2024-$155.50M–
FY2023Dec 31, 2023-$116.36M–
FY2022Dec 31, 2022-$94.63M–
FY2021Dec 31, 2021-$75.44M–
FY2020Dec 31, 2020-$37.27M–
FY2019Dec 31, 2019-$2.75M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$12.80M–
Q1 FY2026Mar 31, 2026-$19.23M–
Q4 FY2025Dec 31, 2025-$17.79M–
Q3 FY2025Sep 30, 2025-$21.08M–
Q2 FY2025Jun 30, 2025-$40.60M–
Q1 FY2025Mar 31, 2025-$48.86M–
Q4 FY2024Dec 31, 2024-$47.66M–
Q3 FY2024Sep 30, 2024-$32.27M–
Q2 FY2024Jun 30, 2024-$45.30M–
Q1 FY2024Mar 31, 2024-$30.27M–
Q4 FY2023Dec 31, 2023-$25.10M–
Q3 FY2023Sep 30, 2023-$36.22M–
Q2 FY2023Jun 30, 2023-$24.76M–
Q1 FY2023Mar 31, 2023-$30.28M–
Q4 FY2022Dec 31, 2022-$31.24M–
Q3 FY2022Sep 30, 2022-$18.50M–
Q2 FY2022Jun 30, 2022-$24.40M–
Q1 FY2022Mar 31, 2022-$20.50M–
Q4 FY2021Dec 31, 2021-$19.87M–
Q3 FY2021Sep 30, 2021-$22.51M–
Q2 FY2021Jun 30, 2021-$19.40M-349.7%
Q1 FY2021Mar 31, 2021-$13.67M–
Q4 FY2020Dec 31, 2020-$16.49M-144.9%
Q3 FY2020Sep 30, 2020-$15.79M–
Q2 FY2020Jun 30, 2020$7.77M–
Q1 FY2020Mar 31, 2020-$12.77M–
Q4 FY2019Dec 31, 2019$36.74M–
Q3 FY2019Sep 30, 2019-$14.88M–

More Pliant Therapeutics figures

See a number that looks wrong?